Medical Crossfire® in ALL
CME Lunch Symposium
Friday, Nov. 30
1:30PM-4:30PM
Registration & Lunch:
12:30PM-1:30PM
Marriott Marquis San Diego Marina
Lunch: Grand Ballroom 8-9, Lobby Level
Meeting: Grand Ballroom 8-9, Lobby Level
333 W. Harbor Dr. San Diego, CA 92101

Benefits of Attending:

  • Develop individualized treatment strategies for your patients
  • Fully understand the advent of novel immune therapies
  • Integrate MRD status, and immunophenotype into risk stratification

Overview:

Acute lymphoblastic leukemia can present at any stage of life. While great progress is being made in the understanding and pathophysiology of ALL, as well as development of targeted agents for the treatment of patients with this disease, a “one-size-fits-all” approach to treatment is no longer enough.

The addition of tyrosine kinase inhibitors, monoclonal antibodies, and novel immune therapies (including and beyond CAR T cells), to the treatment of ALL has radically changed the way we must approach our patients. Individualized treatment based on immunophenotypic, cytogenetic, and molecular features is the future of care. We understand how uniquely challenging updating practice can be for busy clinicians like you.

Please join us for lunch on Friday, November 30 for an open exchange of ideas, new data, and expert opinion

Program Chair:

Elias Jabbour, MD
Associate Professor, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Integrating New Therapies in AML
CME Dinner Symposium
Friday, Nov. 30
7:00PM-10:00PM
Registration & Dinner:
6:00PM-7:00PM
Manchester Grand Hyatt San Diego
Dinner: Grand Hall D, Lobby Level
Symposia: Grand Hall D, Lobby Level
1 Market Pl, San Diego, CA 92101

Benefits of Attending:

  • Integrate targeted therapies into your AML treatment
  • Prepare for the next generation of FLT3 and IDH inhibitors
  • Proactively manage treatment-related toxicities

Overview:

Keeping up with the unprecedented development of new therapies for patients with acute myeloid leukemia (AML) has become particularly challenging for busy clinicians. The past 2 years have seen nearly a dozen new agents approved or in review by regulatory authorities, including inhibitors of FLT3, isocitrate dehydrogenase (IDH), and BCL-2, as well as hypomethylating agents, anti-CD33 agents, and novel cytotoxic formulations. Moreover, use of these new therapies is increasingly being tied to molecular markers. These developments have changed the paradigm of care for patients with AML.

To help you better navigate the changing therapeutic landscape, we are pleased to present New Therapies for Better Patient Outcomes in Acute Myeloid Leukemia: Integration of Recent Data Sets Into Clinical Practice, a cutting-edge program designed to help you apply with confidence the latest therapeutic developments for your patients with AML.

Program Chair:

Naval G. Daver, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Recent Advances in GvHD
CME Lunch Symposium
Friday, Nov. 30
1:30PM-4:30PM
Registration & Lunch:
12:30PM-1:30PM
Manchester Grand Hyatt San Diego
Lunch: Grand Hall D, Lobby Level
Symposia: Grand Hall D, Lobby Level
1 Market Pl, San Diego, CA 92101

Benefits of Attending:

  • Learn strategies to prevent the development of GvHD
  • Evaluate the efficacy and safety of new regimens to treat GvHD
  • Understand the role of biomarkers in predicting treatment response

Overview:

A great deal of progress has been made in the understanding of the mechanistic underpinnings of acute and chronic graft-versus host disease (GvHD). It is important for you to be able to apply up-to-the-minute clinical data related to recent approvals and late-stage compounds to maximize outcomes for your patients. This includes efficacy considerations, as well as development of strategies to identify and mitigate predictable treatment-related adverse events in a timely fashion. To help you optimize the management of your patients at risk of developing acute or chronic GvHD, this educational curriculum includes the most recent clinical advances in novel diagnostic, therapeutic, and patient counseling strategies that will potentially impact management of patients with acute and chronic GvHD.

This symposium is designed to educate audiences in an innovative, engaging format, and will include a mix of didactic lecture, case studies that reflect challenges faced by community healthcare professionals, panel discussion, and Q&A. The program is designed to be fast-paced and highly interactive between faculty and audience. Case studies and panel discussions will be used by the Chair to challenge faculty on their treatment decisions, and to provide the audience an opportunity to reflect on best practices and their own clinical decisions for higher educational engagement. This program will arm you with the most up-to-date information for personalizing care for your patients at risk of developing acute or chronic GvHD.

Program Chair:

Corey Cutler, MD, MPH, FRCP(C)
Associate Professor of Medicine
Harvard Medical School
Division of Hematologic Oncology
Dana-Farber Cancer Institute
Boston, MA

Solving the Mystery of Rare Heme
CME Lunch Symposium
Friday, Nov. 30
1:30PM-4:30PM
Registration & Lunch:
12:30PM-1:30PM
Marriott Marquis San Diego Marina
Lunch: Grand Ballroom 1-4, Lobby Level
Meeting: Grand Ballroom 1-4, Lobby Level
333 W. Harbor Dr. San Diego, CA 92101

Benefits of Attending:

  • Improve your differential diagnosis abilities
  • Recognize the signs of rare disorders
  • Learn new strategies to treat underlying disease

Overview:

Hematologists and primary care physicians play a pivotal role in the diagnosis and management of patients who present with hematologic symptoms of unknown origin. This program is designed to raise your awareness of rare hematologic disorders (ie, Gaucher's disease, paroxysmal nocturnal hemoglobinuria, thrombotic thrombocytopenic purpura, and immune thrombocytopenia) and improve your ability to provide accurate and early diagnosis, as well as appropriate therapy for your patients with these conditions. The program will feature a mixed format of didactic lectures, panel discussions, and interactive clinical case studies. Throughout the case presentations, the program faculty of renowned experts in uncommon blood disorders will encourage you to seek clues from the clinical history and presentation, consider the differential diagnoses, and assess which tests are required to secure a definitive diagnosis. During the activity, the faculty will review the latest clinical data, share their best practices, review new and emerging strategies in the context of existing diagnostic and therapeutic algorithms, and offer opportunities for you to ask questions and share your own perspectives.

Program Chair:

Pramod K. Mistry, MD, PhD, FRCP, FAASLD
Professor of Medicine and Pediatrics
Professor of Cellular & Molecular Physiology
Department of Internal Medicine (Digestive Diseases)
Yale University School of Medicine
New Haven, CT

Advancing PV, Myelofibrosis, and MPNs
CME Lunch Symposium
Friday, Nov. 30
1:30PM-4:30PM
Registration & Lunch:
12:30PM-1:30PM
Marriott Marquis San Diego Marina
Lunch: Grand Ballroom 5-6, Lobby Level
Meeting: Grand Ballroom 5-6, Lobby Level
333 W. Harbor Dr. San Diego, CA 92101

Benefits of Attending:

  • Translate the latest clinical data into treatment practice
  • Understand novel mechanisms that affect the JAK-STAT pathway
  • Develop new management strategies for your patients with MPNs

Overview:

Your management of patients with myelofibrosis (MF) that occurs as a primary or a late occurrence in the evolution of essential thrombocythemia (ET) and polycythemia vera (PV) requires careful diagnosis and classification based on histology, molecular characteristics, and risk stratification. A great deal of translation research from bench to beside for emerging novel compounds that target the JAK-STAT pathway has resulted in the development and application of pathway-specific therapeutic strategies.

As the volume of evidence supporting the role of targeted therapies continues to accumulate, it is important for you to understand novel mechanistic approaches to targeting mediators of tumor-promoting inflammation, and to apply clinical data to the development of treatment paradigms that maximize outcomes for your patients. This includes efficacy considerations, as well as development of strategies to identify and mitigate predictable treatment-related adverse events in a timely fashion.

To help you optimize the management of your patients with PV and MF, this activity will bring together renowned international experts in myeloproliferative neoplasm (MPN) treatment and clinical research in an in-depth tumor board format, which will assess the clinical impact of recent and emerging trial data on the development of treatment paradigms. A series of case presentations will be discussed, with clinical trial data tightly integrated to illuminate MPN treatment decisions related to frontline-and-beyond therapies, sequencing, switching, and patient and disease characteristics. Future directions in the field will also be addressed and considered with regard to how recent developments and highly anticipated trials may shape care in the near future.

The program will give you the opportunity to reflect on best practices and your own clinical decisions to personalize care for your patients with PV and MF.

Program Chair:

Brady Lee Stein, MD
Associate Professor of Medicine
Feinberg School of Medicine
Northwestern University
Chicago, IL

Cases in Hemolytic Anemia
CME Lunch Symposium
Friday, Nov. 30
1:30PM-4:30PM
Registration & Lunch:
12:30PM-1:30PM
Marriott Marquis San Diego Marina
Lunch: Grand Ballroom 10-13, Lobby Level
Meeting: Grand Ballroom 10-13, Lobby Level
333 W. Harbor Dr. San Diego, CA 92101

Benefits of Attending:

  • Differentiate between underlying causes of hemolytic anemia
  • Understand the pathophysiology of uncommon disorders
  • Update treatment paradigms with new strategies

Overview:

Your management of patients with hematologic malignancy-induced anemias and other anemias require careful diagnosis and classification of the underlying cause of symptoms. Your ability to distinguish between treatment-induced anemias, disease-related anemias, and anemias of genetic origin is essential before beginning treatment strategies. Often, you must determine whether treatment should address the anemia itself or its underlying cause. When managing myelodysplastic syndromes, pyruvate kinase deficiency (PKD), beta-thalassemia and other hematologic disorders, the treatment of anemia is an essential aspect of patient care.

To help you optimize the management of your patients with hemolytic anemias, we have developed an exciting live satellite luncheon symposium, with interactive audience response system, a patient video, and live webcast to national remote audiences preceding the American Society of Hematology (ASH) 60th Annual Meeting, highlighting recent clinical advances in novel diagnostic, therapeutic, and patient counseling strategies to maximize treatment and management of your patients with hemolytic anemias. This includes efficacy considerations, as well as development of strategies to identify and mitigate predictable treatment-related adverse events in a timely fashion.

This activity features expert commentary and insights from renowned clinical educators who will contextualize data highlights and key findings through an innovative, engaging format, including a mix of didactic lectures, case studies that reflect challenges facing community hematologists when determining clinical trial options for patients, panel discussion, and Q&A. The program will give you the opportunity to reflect on best practices and your own clinical decisions to personalize care for your patients with hemolytic anemia.

Program Chair:

Janet Kwiatkowski, MD, MSCE
Director, The Thalassemia Center
Children's Hospital of Philadelphia
Philadelphia, PA